Providence Advances Surgical Robotics Program with Multi-System, National Contract for PROCEPT BioRobotics AquaBeam Systems
19 9월 2022 - 9:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, and Providence, a
not-for-profit health system serving the Western U.S., today
announced a multi-system, national contract to acquire AquaBeam
Robotic Systems. As of June 30, 2022, Providence had seven AquaBeam
Robotic Systems installed across California and Texas.
“For men affected by benign prostatic hyperplasia, Aquablation
therapy’s safety and efficacy profile provides long-term symptom
relief leading to significant improvements in quality of life,”
said Richard Shapiro, M.D., F.A.C.S., on staff at Providence
Cedars-Sinai Tarzana Medical Center and one of the first Providence
urologists to perform the new procedure. “This option appeals to
men who are looking for a long-lasting solution with minimal risk
of irreversible complications.”
“PROCEPT is honored to partner with leading health systems, such
as Providence, that are committed to advancing patient care through
next-generation innovations and we look forward to supporting their
growing programs across the western United States,” said Sham
Shiblaq, Executive Vice President, Chief Commercial Officer of
PROCEPT. “As we continue to expand our global commercial footprint,
our dedicated team remains focused on accelerating adoption of
Aquablation therapy and bringing this much needed treatment option
to all patients.”
Aquablation therapy combines real-time, multi-dimensional
imaging, automated robotics and heat-free waterjet ablation for
targeted, controlled and immediate removal of prostate tissue.
Combining both cystoscopic visualization and ultrasound imaging,
surgeons can create a personalized treatment plan tailored to each
patient’s anatomy. Once the personalized treatment map is complete,
the robotically controlled, heat-free waterjet ablates the prostate
tissue, avoiding critical structures to preserve sexual function
and continence.1,2,3
For more information on Providence, visit www.providence.org
For more information on Aquablation therapy, visit
www.aquablation.com
About ProvidenceProvidence is a national,
not-for-profit Catholic health system comprising a diverse family
of organizations and driven by a belief that health is a human
right. With 52 hospitals, over 900 physician clinics, senior
services, supportive housing, and many other health and educational
services, the health system and its partners employ nearly 120,000
caregivers serving communities across seven states – Alaska,
California, Montana, New Mexico, Oregon, Texas, and Washington,
with system offices in Renton, Wash., and Irvine, Calif.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT develops, manufactures and sells the AquaBeam Robotic
System, an advanced, image-guided, surgical robotic system for use
in minimally-invasive urologic surgery with an initial focus on
treating benign prostatic hyperplasia, or BPH. BPH is the most
common prostate disease and impacts approximately 40 million men in
the United States. PROCEPT designed Aquablation therapy to deliver
effective, safe and durable outcomes for males suffering from lower
urinary tract symptoms, or LUTS, due to BPH that are independent of
prostate size and shape or surgeon experience. PROCEPT has
developed a significant and growing body of clinical evidence,
which includes nine clinical studies and over 100 peer-reviewed
publications, supporting the benefits and clinical advantages of
Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including with respect to the Company’s projected financial
performance for full year 2022, statements regarding the potential
utilities, values, benefits and advantages of Aquablation® therapy
performed using PROCEPT BioRobotics’ products, including AquaBeam®
Robotic System, which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements. Forward-looking statements are only
predictions based on our current expectations, estimates, and
assumptions, valid only as of the date they are made, and subject
to risks and uncertainties, some of which we are not currently
aware. Forward-looking statements may include statements regarding
financial guidance, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
including descriptions of the Company’s revenues, gross margin,
profitability, operating expenses, installed base growth,
commercial momentum, reimbursement coverage, overall business
strategy, and other global events on the Company and its
operations. Forward‐looking statements should not be read as a
guarantee of future performance or results and may not necessarily
be accurate indications of the times at, or by, which such
performance or results will be achieved. These forward‐looking
statements are based on the Company’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. These risks and uncertainties are
described more fully in the section titled “Risk Factors” in the
Company’s filings with the Securities and Exchange Commission (the
“SEC”), including the Company’s annual report on From 10-K filed
with the SEC on March 22, 2022, and in the Company’s other periodic
reports filed with the SEC. PROCEPT BioRobotics does not undertake
any obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward‐looking statements contained
herein. These forward-looking statements should not be relied upon
as representing PROCEPT BioRobotics’ views as of any date
subsequent to the date of this press release.
Important Safety
Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects visit
https://aquablation.com/safety-information/
Investor Contact:Matt Bacso, CFA VP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024